Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healing II: Complications01:24

Healing II: Complications

Complications during healing arise when tissue repair is altered by local or systemic factors. These changes involve abnormal collagen deposition, altered biomechanics, and reduced vascular supply, impairing restoration of normal structure and function.Loss of FunctionScar tissue differs significantly from the original tissue it replaces. In the skin, fibrosis lacks adnexal structures such as hair follicles, sebaceous glands, and sweat glands. Their absence reduces tactile sensitivity, impairs...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Peptic Ulcer Disease III: Clinical Manifestations and Complications01:25

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strategic modulation to avoid radiation toxicities for brain integrity (SMART-BRAIN).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Encouraging Local Control With Pediatric Spatially Fractionated Radiation Therapy.

Advances in radiation oncology·2026
Same author

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same author

Outcomes following radiotherapy for atypical teratoid/rhabdoid tumor in combination with surgery and intensive chemotherapy: A report from Children's Oncology Group study ACNS0333.

Neuro-oncology pediatrics·2026
Same author

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.

Cancer·2026
Same author

Fetal study of soft tissue anomalies and osteocartilage anlagen defects in congenital club foot.

Journal of pediatric orthopedics. Part B·2026

Related Experiment Video

Updated: May 18, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Normal tissue complications from low-dose proton therapy.

Anita Mahajan1

  • 1Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.amahajan@mdanderson.org

Health Physics
|October 4, 2012
PubMed
Summary

Proton therapy may reduce radiation side effects in children by lowering the dose to normal tissues. While biological effects are similar to photon therapy, reduced low-dose exposure is expected to decrease toxicities.

More Related Videos

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: May 18, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

  • Radiation Oncology
  • Pediatric Oncology
  • Medical Physics

Background:

  • Proton therapy offers reduced integral radiation dose to normal tissues, potentially decreasing late side effects.
  • Children are particularly vulnerable to radiation risks, making proton therapy attractive for pediatric malignancies.
  • Improving survival rates in pediatric cancers necessitate strategies to mitigate long-term radiation effects.

Purpose of the Study:

  • To evaluate the potential benefits of proton therapy in reducing toxicities, especially in the low-dose regions of radiosensitive organs.
  • To review existing photon therapy data for radiosensitive structures due to limited clinical information on low-dose proton therapy.
  • To discuss the expected reduction in early and late toxicities and potential benefits for neuro-cognitive sequelae and secondary malignancies.

Main Methods:

  • Review of clinical data and scientific literature on proton and photon therapy outcomes.
  • Evaluation of dose distribution characteristics of proton therapy compared to photon therapy.
  • Analysis of biological effectiveness and dose-response relationships for protons.

Main Results:

  • Proton therapy is expected to reduce early and late toxicities (e.g., vomiting, mucositis, cardiovascular, pulmonary, developmental effects) due to a reduced or eliminated low-dose radiation bath.
  • While a relative biological effectiveness (RBE) of 1.1 is used for dose calculation (GyEq), current data do not definitively show different biological outcomes compared to photon therapy at equivalent doses.
  • Uncertainty in dose deposition at the Bragg peak necessitates avoiding critical structures.

Conclusions:

  • Normal tissue tolerance to proton radiotherapy is likely similar to photon radiation at equivalent biologic doses.
  • Proton therapy is anticipated to lower the risk of normal tissue toxicity due to reduced dose delivery outside the target area.
  • The potential for decreased long-term side effects makes proton therapy a promising option for pediatric cancer patients.